Kinetic characterisation of covalent inhibitors on the PHERAstar

Available on demand

Due to safety concerns, the pharmaceutical industry has long avoided covalent drug approaches. More recent success stories have shown that carefully tuned reactivity and specific complementarity of covalent compounds to their target can give rise to drugs with a range of advantages, particularly in the cancer field. This webinar, presented by Catherine Wark from BMG Labtech and Dr Agnes Martin, a principal scientist from Cancer Research UK, covers biochemical strategies for characterising covalent compounds in vitro, exemplified by the recent discovery of a new covalent inhibitor targeting the hitherto undruggable cancer target USP7.